19:10
Unknown
Global hypoglycemic agents market's best-selling drug is Merck's sitagliptin and 2011 sales of $ 3.3 billion. canagliflozin once approved by the FDA, with Sitagliptin compete.
Johnson developed canagliflozin to become the focus of the market. Phase III clinical trial data show that the drug reduces the patient's blood sugar levels better than Merck's sitagliptin (Januvia). canagliflozin once approved by the FDA, Johnson & Johnson will become the first hypoglycemic agents, with the market leader, West column Ting competing the latter 2011 sales of $ 3.3 billion.
new hypoglycemic agents canagliflozin belongs to a class known as the sodium - glucose transporter type 2 (SGLT2) inhibitor by blocking the kidney blood glucose reabsorption and increase the excretion of glucose in the urine, to reduce the body's blood sugar levels.
Innovative ways to control blood sugar
The clinical experts said canagliflozin not a direct treatment, but the methods through innovative ways to control the patient's blood sugar level, for the treatment of other serious diseases brought revelation. , Including sitagliptin, most of the working mechanism of hypoglycemic agents secreted by control in patients with insulin to regulate blood sugar levels.
In Phase III clinical trials, canagliflozin carry nine randomized clinical trials, recruited a total of nearly 10,300 patients, is the largest international multi-center clinical trial for patients with type 2 diabetes. The results show that superior to sitagliptin and another old drug glimepiride in lowering blood glucose, canagliflozin and the canagliflozin the more significant role in weight loss compared with glimepiride the canagliflozin induced hypoglycemia events less.
At the end of last month, Johnson & Johnson has FDA submitted canagliflozin listing application is expected to be approved in the next year. Wells Fargo Securities analyst in New York is the peak of the drug sales in 2013 are expected to be $ 122 million, will grow to $ 667 million in 2016.
Critical review of the security
Canagliflozin treatment of type 2 diabetes in innovative ways, the side effects are not clear. Many diabetes patients with kidney disease, is unclear long after taking the drug, whether it will further damage the kidneys.
So far, canagliflozin lead to a higher rate of reproductive tract infections, urinary tract infections, and voiding demand. Since 2007, GlaxoSmithKline's Avandia cause heart attacks in patients, and in a subsequent study showed that the drug might produce harmful effects in patients, the FDA strengthened security review of hypoglycemic agents. Bristol-Myers Squibb Dag column net (Dapagliflozin) and AstraZeneca in research hypoglycemic agents were FDA rejection, because the regulatory agency is concerned that these drugs lead to bladder cancer, and breast cancer risk. The research report, the canagliflozin the clinical data is not related to cancer.
According to IMS statistics, last year, all therapeutic categories in the United States, hypoglycemic agents market growth came in the first three, representing an increase of 10.7% over 2010, reaching $ 19.6 billion, the best-selling hypoglycemic agents for sitagliptin.
The analysis of think the canagliflozin the reason to be optimistic about the market, because of the early clinical trials of the drug used alone canagliflozin not lead to low blood sugar. Nonetheless, the the canagliflozin lead to urinary tract infections and frequent urination demand may affect the clinical application.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Johnson developed canagliflozin to become the focus of the market. Phase III clinical trial data show that the drug reduces the patient's blood sugar levels better than Merck's sitagliptin (Januvia). canagliflozin once approved by the FDA, Johnson & Johnson will become the first hypoglycemic agents, with the market leader, West column Ting competing the latter 2011 sales of $ 3.3 billion.
new hypoglycemic agents canagliflozin belongs to a class known as the sodium - glucose transporter type 2 (SGLT2) inhibitor by blocking the kidney blood glucose reabsorption and increase the excretion of glucose in the urine, to reduce the body's blood sugar levels.
Innovative ways to control blood sugar
The clinical experts said canagliflozin not a direct treatment, but the methods through innovative ways to control the patient's blood sugar level, for the treatment of other serious diseases brought revelation. , Including sitagliptin, most of the working mechanism of hypoglycemic agents secreted by control in patients with insulin to regulate blood sugar levels.
In Phase III clinical trials, canagliflozin carry nine randomized clinical trials, recruited a total of nearly 10,300 patients, is the largest international multi-center clinical trial for patients with type 2 diabetes. The results show that superior to sitagliptin and another old drug glimepiride in lowering blood glucose, canagliflozin and the canagliflozin the more significant role in weight loss compared with glimepiride the canagliflozin induced hypoglycemia events less.
At the end of last month, Johnson & Johnson has FDA submitted canagliflozin listing application is expected to be approved in the next year. Wells Fargo Securities analyst in New York is the peak of the drug sales in 2013 are expected to be $ 122 million, will grow to $ 667 million in 2016.
Critical review of the security
Canagliflozin treatment of type 2 diabetes in innovative ways, the side effects are not clear. Many diabetes patients with kidney disease, is unclear long after taking the drug, whether it will further damage the kidneys.
So far, canagliflozin lead to a higher rate of reproductive tract infections, urinary tract infections, and voiding demand. Since 2007, GlaxoSmithKline's Avandia cause heart attacks in patients, and in a subsequent study showed that the drug might produce harmful effects in patients, the FDA strengthened security review of hypoglycemic agents. Bristol-Myers Squibb Dag column net (Dapagliflozin) and AstraZeneca in research hypoglycemic agents were FDA rejection, because the regulatory agency is concerned that these drugs lead to bladder cancer, and breast cancer risk. The research report, the canagliflozin the clinical data is not related to cancer.
According to IMS statistics, last year, all therapeutic categories in the United States, hypoglycemic agents market growth came in the first three, representing an increase of 10.7% over 2010, reaching $ 19.6 billion, the best-selling hypoglycemic agents for sitagliptin.
The analysis of think the canagliflozin the reason to be optimistic about the market, because of the early clinical trials of the drug used alone canagliflozin not lead to low blood sugar. Nonetheless, the the canagliflozin lead to urinary tract infections and frequent urination demand may affect the clinical application.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Posted in: Business Opportunities
0 comments:
Post a Comment